Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.09) by 7.34 percent. This is a 2.88 percent increase over losses of $(1.04) per share from the same period last year. The company reported quarterly sales of $898.000 thousand which beat the analyst consensus estimate of $411.429 thousand by 118.26 percent. This is a 53.95 percent decrease over sales of $1.950 million the same period last year.